Market Place
Sourcing Support
Athira exploring strategic alternatives after Alzheimer’s failure
08 Nov 2024 //
BIOPHARMADIVE
Athira Pharma Q3 2024 Results & Business Updates
07 Nov 2024 //
GLOBENEWSWIRE
Athira Pharma Presents LIFT-AD Trial Results At CTAD 2024
22 Oct 2024 //
GLOBENEWSWIRE
After Alzheimer`s stumble, Athira lays off 70% of workforce
21 Sep 2024 //
FIERCE BIOTECH
Athira Pharma Focuses on Advancing ATH-1105 Treatment
17 Sep 2024 //
GLOBENEWSWIRE
Athira Pharma`s Alzheimer`s drug fails in mid-to-late stage trial
04 Sep 2024 //
GLOBENEWSWIRE
Athira Pharma Reports Q2 2024 Results And Pipeline Updates
01 Aug 2024 //
GLOBENEWSWIRE
GigaGen`s IND For GIGA-2339 HBV Treatment Cleared By FDA
31 Jul 2024 //
GLOBENEWSWIRE
Athira Pharma Completes LIFT-AD Trial Of Fosgonimeton In Alzheimer`s
09 Jul 2024 //
GLOBENEWSWIRE
Athira To Host Webinar On Fosgonimeton For Alzheimer`s Disease
12 Jun 2024 //
GLOBENEWSWIRE
Athira Pharma Completes First Cohort in Ph1 Trial of ATH-1105, an Oral (ALS)
11 Jun 2024 //
GLOBENEWSWIRE
Athira Pharma to Participate in Upcoming June Conferences
29 May 2024 //
GLOBENEWSWIRE
Athira Pharma Announces Proposed Settlement of Stockholder Derivative Action
17 May 2024 //
GLOBENEWSWIRE
Athira Pharma Reports Q1 2024 Results, Pipeline, Business Updates
15 May 2024 //
GLOBENEWSWIRE
Athira Pharma to Participate in Upcoming May Conferences
02 May 2024 //
GLOBENEWSWIRE
Athira Appoints Javier San Martin As CMO
15 Apr 2024 //
GLOBENEWSWIRE
Athira: Fosgonimeton Alzheimer`s Preclinical Data Published
11 Apr 2024 //
GLOBENEWSWIRE
Athira Pharma Announces Upcoming Poster Presentation at AAN 2024 Annual Meeting
03 Apr 2024 //
GLOBENEWSWIRE
Athira Presents Data Supporting Therapeutic Potential of Fosgonimeton
08 Mar 2024 //
GLOBENEWSWIRE
Athira Pharma Reports Full Year 2023 Financial Results
22 Feb 2024 //
GLOBENEWSWIRE
Athira Pharma Announces Publication in Frontiers in Neuroscience
08 Feb 2024 //
GLOBENEWSWIRE
Athira Pharma Provides 2024 Clinical Pipeline Outlook and Business Update
08 Jan 2024 //
GLOBENEWSWIRE
Athira Pharma Completes Enrollment of Phase 2/3 LIFT-AD Trial of Fosgonimeton
03 Jan 2024 //
GLOBENEWSWIRE
Athira Pharma Announces Encouraging Results from Phase 2 Trial of Fosgonimeton
12 Dec 2023 //
GLOBENEWSWIRE
Athira’s losing streak continues with ph. 2 failure in dementia
12 Dec 2023 //
FIERCE BIOTECH
Athira Pharma to Participate in Sidoti December Small Cap Investor Conference
29 Nov 2023 //
GLOBENEWSWIRE
Athira Pharma Announces Presentation at Motor Neurone Disease Association
28 Nov 2023 //
GLOBENEWSWIRE
Athira Presents Data Highlighting Fosgonimeton™s Neuroprotective Effects
15 Nov 2023 //
GLOBENEWSWIRE
Athira Pharma Reports Third Quarter 2023 Financial Results
09 Nov 2023 //
GLOBENEWSWIRE
Athira Pharma to Participate in Jefferies London Healthcare Conference
08 Nov 2023 //
GLOBENEWSWIRE
Athira Pharma Presents Preclinical Data Further Supporting ATH-1105
05 Oct 2023 //
GLOBENEWSWIRE
Athira Pharma to Participate in Upcoming October Conferences
28 Sep 2023 //
GLOBENEWSWIRE
Athira Pharma to Participate in the 2023 Cantor Fitzgerald Global Conference
19 Sep 2023 //
GLOBENEWSWIRE
Athira Pharma Reports Second Quarter 2023 Financial Results
10 Aug 2023 //
GLOBENEWSWIRE
Athira Presents Phase 2 Data Correlating Improvements in Biomarkers of Neurodegeneration
17 Jul 2023 //
GLOBENEWSWIRE
Athira Pharma Announces Upcoming Presentations at the AAIC 2023
06 Jul 2023 //
GLOBENEWSWIRE
Athira Pharma to Participate in Upcoming June Conferences
31 May 2023 //
GLOBENEWSWIRE
Athira Pharma Appoints Andrew Gengos as CFO and Chief Business Officer
22 May 2023 //
GLOBENEWSWIRE
Athira Pharma Reports First Quarter 2023 Financial Results
11 May 2023 //
GLOBENEWSWIRE
Athira Pharma to Participate in Upcoming May Investor Conferences
08 May 2023 //
GLOBENEWSWIRE
Athira Pharma Presents New Clinical and Preclinical Data at the (AAN) 2023
25 Apr 2023 //
GLOBENEWSWIRE
Athira Pharma Announces Upcoming Presentations at AAN 2023 Annual Meeting
11 Apr 2023 //
GLOBENEWSWIRE
Athira Pharma Presents Data Supporting Therapeutic Potential of Fosgonimeton
28 Mar 2023 //
GLOBENEWSWIRE
Athira Pharma Reports Full Year 2022 Financial Results
23 Mar 2023 //
GLOBENEWSWIRE
Athira Pharma to Present at Upcoming Neuroscience Focused Investor Conferences
08 Mar 2023 //
GLOBENEWSWIRE
Athira to Present Data Supporting Therapeutic Potential of Enhancing HGF/MET Neurotrophic System
06 Mar 2023 //
GLOBENEWSWIRE
Athira Pharma Announces Publication in Journal of Alzheimer`s Disease
01 Feb 2023 //
GLOBENEWSWIRE
Athira Pharma Announces Promotion of Kevin Church, Ph.D., to CSO
31 Jan 2023 //
GLOBENEWSWIRE
Athira Pharma Provides 2023 Pipeline Outlook
05 Jan 2023 //
GLOBENEWSWIRE
Athira Pharma Announces Publication of Fosgonimeton Preclinical Results
21 Dec 2022 //
GLOBENEWSWIRE
Athira Pharma Presents Preclinical Data Supporting Therapeutic of ATH-1105
05 Dec 2022 //
GLOBENEWSWIRE
Athira Pharma to Host Virtual R&D Event on December 7, 2022, from 2:00
01 Dec 2022 //
GLOBENEWSWIRE
Athira Pharma Highlights Therapeutic Potential of Fosgonimeton in Presentation
29 Nov 2022 //
GLOBENEWSWIRE
Athira to Present Data Highlighting Therapeutic Potential of ATH-1105 in ALS
28 Nov 2022 //
GLOBENEWSWIRE
Athira to Present Biomarker Data from ACT-AD Phase 2 Study of Fosgonimeton
21 Nov 2022 //
GLOBENEWSWIRE
Athira Pharma Presents Preclinical Data Supporting Potential of HGF/MET Platform
16 Nov 2022 //
GLOBENEWSWIRE
Athira Pharma to Present Preclinical Data Highlighting Therapeutic of HGF/MET
07 Nov 2022 //
GLOBENEWSWIRE
Athira plots an Alzheimer`s comeback after scandal
06 Sep 2022 //
ENDPTS
Athira Pharma Provides Update on Plans for Ongoing LIFT-AD of Fosgonimeton
06 Sep 2022 //
GLOBENEWSWIRE
Athira Pharma Reports Second Quarter 2022 Financial Results
15 Aug 2022 //
GLOBENEWSWIRE
